Drugs / Cytokine-treated Veto Cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03622788 | Aug 2019 → Dec 2027 expected | Hodgkins lymphoma, acute myeloid leukemia, aplastic anemia, bone marrow failure syndrome +6 | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cytokine-treated Veto Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03622788 ↗ |
| Modality | Cell therapy | “Cytokine-treated veto cells may help the transplanted donor cells to develop and grow in recipients” NCT03622788 ↗ |
| Route | Intravenous | “cytokine-treated veto cells IV over 30-60 minutes on day +7” NCT03622788 ↗ |